473 related articles for article (PubMed ID: 17914965)
1. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
Fujita N; Sugimoto R; Urawa N; Araki J; Mifuji R; Yamamoto M; Horiike S; Tanaka H; Iwasa M; Kobayashi Y; Adachi Y; Kaito M
J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
[TBL] [Abstract][Full Text] [Related]
2. Iron and hepatitis C: beginning to make sense.
Bassett ML
J Gastroenterol Hepatol; 2007 Nov; 22(11):1703-4. PubMed ID: 17914937
[No Abstract] [Full Text] [Related]
3. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
4. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
5. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
6. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
Kohjima M; Yoshimoto T; Enjoji M; Fukushima N; Fukuizumi K; Nakamura T; Kurokawa M; Fujimori N; Sasaki Y; Shimonaka Y; Murata Y; Koyama S; Kawabe K; Haraguchi K; Sumida Y; Harada N; Kato M; Kotoh K; Nakamuta M
World J Gastroenterol; 2015 Mar; 21(11):3291-9. PubMed ID: 25805936
[TBL] [Abstract][Full Text] [Related]
7. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
Sikorska K; Stalke P; Izycka-Swieszewska E; Romanowski T; Bielawski KP
Med Sci Monit; 2010 Mar; 16(3):CR137-143. PubMed ID: 20190684
[TBL] [Abstract][Full Text] [Related]
8. Hepatic iron influences responses to combination therapy with peginterferon alfa and ribavirin in chronic hepatitis C.
Lin TJ; Liao LY; Lin CL; Chang TA; Liu SO
Hepatogastroenterology; 2008; 55(85):1412-5. PubMed ID: 18795701
[TBL] [Abstract][Full Text] [Related]
9. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
Hofer H; Osterreicher C; Jessner W; Penz M; Steindl-Munda P; Wrba F; Ferenci P
J Hepatol; 2004 Jun; 40(6):1018-22. PubMed ID: 15158344
[TBL] [Abstract][Full Text] [Related]
10. Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C.
Nanba S; Ikeda F; Baba N; Takaguchi K; Senoh T; Nagano T; Seki H; Takeuchi Y; Moritou Y; Yasunaka T; Ohnishi H; Miyake Y; Takaki A; Nouso K; Iwasaki Y; Yamamoto K
J Clin Pathol; 2016 Mar; 69(3):226-33. PubMed ID: 26290259
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.
Ishizu Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
J Gastroenterol Hepatol; 2012 Jun; 27(6):1112-6. PubMed ID: 22098610
[TBL] [Abstract][Full Text] [Related]
12. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.
Fabris P; Brown D; Tositti G; Bozzola L; Giordani MT; Bevilacqua P; de Lalla F; Webster GJ; Dusheiko G
J Clin Virol; 2004 Mar; 29(3):160-6. PubMed ID: 14962784
[TBL] [Abstract][Full Text] [Related]
13. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study.
Manolakopoulos S; Bethanis S; Liapi C; Stripeli F; Sklavos P; Margeli A; Christidou A; Katsanika A; Vogiatzakis E; Tzourmakliotis D; Theocharis S
BMC Gastroenterol; 2007 May; 7():17. PubMed ID: 17540037
[TBL] [Abstract][Full Text] [Related]
14. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
[TBL] [Abstract][Full Text] [Related]
16. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection.
Lee CM; Kee KM; Hung CH; Eng HL; Chang CH; Huang CM; Wang JH; Hu TH; Lu SN; Changchien CS; Chen WJ
Antivir Ther; 2006; 11(1):17-23. PubMed ID: 16518956
[TBL] [Abstract][Full Text] [Related]
17. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
Fujita N; Horiike S; Sugimoto R; Tanaka H; Iwasa M; Kobayashi Y; Hasegawa K; Ma N; Kawanishi S; Adachi Y; Kaito M
Free Radic Biol Med; 2007 Feb; 42(3):353-62. PubMed ID: 17210448
[TBL] [Abstract][Full Text] [Related]
18. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
Jian Wu Y; Shu Chen L; Gui Qiang W
Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
20. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection.
Pianko S; McHutchison JG; Gordon SC; Heaton S; Goodman ZD; Patel K; Cortese CM; Brunt EM; Bacon BR; Blatt LM
J Interferon Cytokine Res; 2002 Apr; 22(4):483-9. PubMed ID: 12034031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
